{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:23:39Z","timestamp":1791415419572,"version":"4.3.3"},"reference-count":155,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.ejmech.2012.02.033","type":"journal-article","created":{"date-parts":[[2012,2,25]],"date-time":"2012-02-25T15:48:49Z","timestamp":1330184929000},"page":"1-16","source":"Crossref","is-referenced-by-count":143,"special_numbering":"C","title":["Tuberculosis: The drug development pipeline at a glance"],"prefix":"10.1016","volume":"51","author":[{"given":"Baptiste","family":"Villemagne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Crauste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Flipo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain R.","family":"Baulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"D\u00e9prez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Willand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2012.02.033_bib1","series-title":"Global Tuberculosis Control","isbn-type":"print","author":"World Health Organization","year":"2011","ISBN":"https:\/\/id.crossref.org\/isbn\/9789241564380"},{"key":"10.1016\/j.ejmech.2012.02.033_bib2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S1473-3099(09)70025-8","article-title":"Are we really that good at treating tuberculosis?","volume":"9","author":"Cox","year":"2009","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S0140-6736(04)15698-5","article-title":"Scale up: meeting targets in global tuberculosis control","volume":"363","author":"Elzinga","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2012.02.033_bib4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1185449","article-title":"The population dynamics and control of tuberculosis","volume":"328","author":"Dye","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2012.02.033_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1146\/annurev.pharmtox.45.120403.100120","article-title":"The magic bullets and tuberculosis drug targets","volume":"45","author":"Zhang","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3181\/00379727-57-14769","article-title":"Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms","volume":"57","author":"Schatz","year":"1944","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/35030019","article-title":"Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics","volume":"407","author":"Carter","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2012.02.033_bib8","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1073\/pnas.71.10.3814","article-title":"The effects of streptomycin or dihydrostreptomycin binding to 16S RNA or to 30S ribosomal subunits","volume":"71","author":"Garvin","year":"1974","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ejmech.2012.02.033_bib9","first-page":"357","article-title":"Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds","volume":"65","author":"Bernstein","year":"1952","journal-title":"Am. Rev. Tuberc."},{"key":"10.1016\/j.ejmech.2012.02.033_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2958.2004.04120.x","article-title":"The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria","volume":"53","author":"Rengarajan","year":"2004","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib11","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1365-2958.2006.05467.x","article-title":"Mechanisms of action of isoniazid","volume":"62","author":"Timmins","year":"2006","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1099\/00221287-63-1-41","article-title":"Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis","volume":"63","author":"Winder","year":"1970","journal-title":"J.\u00a0Gen. Microbiol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib13","first-page":"511","article-title":"The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice","volume":"65","author":"Malone","year":"1952","journal-title":"Am. Rev. Tuberc."},{"key":"10.1016\/j.ejmech.2012.02.033_bib14","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Zhang","year":"2003","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib16","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1126\/science.1208813","article-title":"Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis","volume":"333","author":"Shi","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2012.02.033_bib17","first-page":"891","article-title":"A\u00a0new synthetic compound with antituberculous activity in mice: ethambutol (dextro-2,2'-(ethylenediimino)-di-l-butanol)","volume":"83","author":"Thomas","year":"1961","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib18","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.93.21.11919","article-title":"The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol","volume":"93","author":"Belanger","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ejmech.2012.02.033_bib19","first-page":"1907","article-title":"Rifampicin, a general review","volume":"21","author":"Binda","year":"1971","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejmech.2012.02.033_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000220462","article-title":"Rifampicin: a new orally active rifamycin","volume":"11","author":"Maggi","year":"1966","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejmech.2012.02.033_bib21","doi-asserted-by":"crossref","first-page":"8949","DOI":"10.1016\/S0021-9258(17)34269-2","article-title":"On the mechanism of rifampicin inhibition of RNA synthesis","volume":"253","author":"McClure","year":"1978","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib22","first-page":"2409","article-title":"Preparation of new pyridinic thioamides active in experimental tuberculosis","volume":"242","author":"Libermann","year":"1956","journal-title":"C.\u00a0R. Hebd. Seances Acad. Sci."},{"key":"10.1016\/j.ejmech.2012.02.033_bib23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.8284673","article-title":"INHA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis","volume":"263","author":"Banerjee","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2012.02.033_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/358591a0","article-title":"The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis","volume":"358","author":"Zhang","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2012.02.033_bib25","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1073\/pnas.97.17.9677","article-title":"Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis","volume":"97","author":"DeBarber","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ejmech.2012.02.033_bib26","doi-asserted-by":"crossref","first-page":"28326","DOI":"10.1074\/jbc.M003744200","article-title":"Activation of the pro-drug ethionamide is regulated in mycobacteria","volume":"275","author":"Baulard","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib27","first-page":"579","article-title":"Susceptibility of mycobacterial d-alanyl-d-alanine synthetase to d-cycloserine","volume":"100","author":"David","year":"1969","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib28","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/jb.179.16.5046-5055.1997","article-title":"Overexpression of the d-alanine racemase gene confers resistance to d-cycloserine in Mycobacterium smegmatis","volume":"179","author":"Caceres","year":"1997","journal-title":"J.\u00a0Bacteriol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1128\/AAC.47.1.283-291.2003","article-title":"Roles of Mycobacterium smegmatis d-Alanine:d-Alanine ligase and d-Alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor d-Cycloserine","volume":"47","author":"Feng","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1021\/cr0404085","article-title":"2-Deoxystreptamine:\u2009central scaffold of aminoglycoside antibiotics\u2020","volume":"105","author":"Busscher","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2012.02.033_bib31","first-page":"583","article-title":"In\u00a0vitro antibacterial properties of nalidixic acid, a new drug active against gram-negative organisms","volume":"161","author":"Deitz","year":"1963","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jac\/dkg208","article-title":"The quinolones: decades of development and use","volume":"51","author":"Emmerson","year":"2003","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0167-4781(98)00126-2","article-title":"DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities","volume":"1400","author":"Levine","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2012.02.033_bib34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1021\/cr030101q","article-title":"Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents","volume":"105","author":"Mitscher","year":"2005","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2012.02.033_bib35","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1128\/AAC.48.4.1281-1288.2004","article-title":"Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity","volume":"48","author":"Aubry","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib36","unstructured":"All the properties were calculated using PipelinePilot from Accelrys."},{"key":"10.1016\/j.ejmech.2012.02.033_bib37","first-page":"340","volume":"35","author":"Gaudilli\u00e8re","year":"2000","journal-title":"Ann. Rep. Med. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib38","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1021\/jm00022a013","article-title":"The synthesis, structure-activity, and structure-side effect relationships of a series of 8-alkoxy- and 5-amino-8-alkoxyquinolone antibacterial agents","volume":"38","author":"Sanchez","year":"1995","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib39","unstructured":"U. Petersen, W. Schr\u00f6ck, D. Habich, A. Krebs, T. Schenke, T. Philipps, K. Grohe, R. Endermann, K.-D. Bremm, K.-G. Metzger, Quinolonecarboxylic acids, US 5480879 A (1996)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib40","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0924-8579(00)00337-X","article-title":"In\u00a0vitro activity of four fluoroquinolones against Mycobacterium tuberculosis","volume":"17","author":"Rodr\u00edguez","year":"2001","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2012.02.033_bib41","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1128\/AAC.50.1.104-112.2006","article-title":"Novel gyrase mutations in quinolone-resistant and \u2013 hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes","volume":"50","author":"Aubry","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib42","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1128\/AAC.47.2.653-657.2003","article-title":"Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis","volume":"47","author":"Hu","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib43","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/AAC.46.4.1022-1025.2002","article-title":"In\u00a0vitro and in\u00a0vivo activities of gatifloxacin against Mycobacterium tuberculosis","volume":"46","author":"Alvirez-Freites","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib44","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1164\/rccm.200407-885OC","article-title":"Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis","volume":"170","author":"Nuermberger","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib45","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.200807-1152OC","article-title":"Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis","volume":"180","author":"Ibrahim","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","article-title":"Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis","volume":"169","author":"Nuermberger","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib47","unstructured":"Moxifloxacin, Tuberculosis, 88 (2008) 127\u2013131."},{"key":"10.1016\/j.ejmech.2012.02.033_bib48","unstructured":"Gatifloxacin, Tuberculosis, 88 (2008) 109\u2013111."},{"key":"10.1016\/j.ejmech.2012.02.033_bib49","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1128\/AAC.44.10.2600-2603.2000","article-title":"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers","volume":"44","author":"Lubasch","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib50","first-page":"605","article-title":"Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"10","author":"Johnson","year":"2006","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/AAC.48.3.780-782.2004","article-title":"Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study","volume":"48","author":"Pletz","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib52","first-page":"65","article-title":"Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis","volume":"14","author":"Wang","year":"2010","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib53","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/rccm.200901-0078OC","article-title":"The tuberculosis trials, substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis","volume":"180","author":"Dorman","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib54","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(09)60333-0","article-title":"Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial","volume":"373","author":"Conde","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2012.02.033_bib55","first-page":"128","article-title":"A\u00a0Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis","volume":"12","author":"Rustomjee","year":"2008","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib56","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.rmed.2006.01.002","article-title":"Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs","volume":"100","author":"Codecasa","year":"2006","journal-title":"Respir. Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib57","unstructured":"Gatifloxacin clinicaltrials.gov (NCT ID: NCT00216385)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib58","unstructured":"Moxifloxacin clinicaltrials.gov (NCT ID: NCT00864383)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib59","unstructured":"J. Guillemont, Quinoline derivatives and their use as mycobacterial inhibitors, WO\/2004\/011436 (2004)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib60","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.medmal.2009.09.007","article-title":"R207910 (TMC207): a new antibiotic for the treatment of tuberculosis","volume":"40","author":"Lounis","year":"2010","journal-title":"Med. Mal. Infect."},{"key":"10.1016\/j.ejmech.2012.02.033_bib61","doi-asserted-by":"crossref","first-page":"e23575","DOI":"10.1371\/journal.pone.0023575","article-title":"Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase","volume":"6","author":"Haagsma","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejmech.2012.02.033_bib62","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A\u00a0diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2012.02.033_bib63","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit c of mycobacterial ATP synthase","volume":"3","author":"Koul","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib64","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01393-08","article-title":"Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue","volume":"53","author":"Haagsma","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib65","doi-asserted-by":"crossref","first-page":"25273","DOI":"10.1074\/jbc.M803899200","article-title":"Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis","volume":"283","author":"Koul","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib66","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.00766-06","article-title":"Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration","volume":"50","author":"Lounis","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib67","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1128\/AAC.47.10.3117-3122.2003","article-title":"Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in\u00a0vivo","volume":"47","author":"Veziris","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib68","doi-asserted-by":"crossref","first-page":"e17556","DOI":"10.1371\/journal.pone.0017556","article-title":"Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis","volume":"6","author":"Veziris","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejmech.2012.02.033_bib69","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1128\/AAC.00566-08","article-title":"Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model","volume":"52","author":"Lounis","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib70","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.01204-07","article-title":"Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis","volume":"52","author":"Rustomjee","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib71","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib72","series-title":"TMC207","author":"De Marez","year":"2011"},{"key":"10.1016\/j.ejmech.2012.02.033_bib73","unstructured":"TMC207 clinicaltrials.gov (NCT ID: NCT01464762)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib74","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1128\/AAC.38.9.2054","article-title":"Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis","volume":"38","author":"Wayne","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib75","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jac\/5.5.499","article-title":"Mechanism of antimicrobial action of metronidazole","volume":"5","author":"Edwards","year":"1979","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib76","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/AAC.43.5.1285","article-title":"Metronidazole therapy in mice infected with tuberculosis","volume":"43","author":"Brooks","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib77","unstructured":"Metronidazole clinicaltrials.gov (NCT ID: NCT00425113)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib78","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1021\/jm00191a025","article-title":"Potential radiosensitizing agents. Dinitroimidazoles","volume":"22","author":"Agrawal","year":"1979","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib79","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0223-5234(89)90034-2","article-title":"Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with antitubercular activity","volume":"24","author":"Nagarajan","year":"1989","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib80","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.37.2.183","article-title":"In\u00a0vitro and in\u00a0vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis","volume":"37","author":"Ashtekar","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib81","unstructured":"W.R. Baker, C. Shaopei, E.L. Keeler, Nitroimidazole antibacterial compounds and methods of use thereof, WO\/1997\/001562 (1997)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib82","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A\u00a0small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2012.02.033_bib83","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1073\/pnas.0508392103","article-title":"Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis","volume":"103","author":"Manjunatha","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ejmech.2012.02.033_bib84","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1128\/AAC.00488-06","article-title":"Mycobacterium leprae is naturally resistant to PA-824","volume":"50","author":"Manjunatha","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib85","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1126\/science.1164571","article-title":"PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release","volume":"322","author":"Singh","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2012.02.033_bib86","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4161\/cib.2.3.7926","article-title":"The mechanism of action of PA-824: novel insights from transcriptional profiling","volume":"2","author":"Manjunatha","year":"2009","journal-title":"Commun. Integr. Biol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib87","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1128\/AAC.49.6.2294-2301.2005","article-title":"Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in\u00a0vitro and in\u00a0vivo models","volume":"49","author":"Lenaerts","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib88","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.49.6.2289-2293.2005","article-title":"Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis","volume":"49","author":"Tyagi","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib89","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00849-10","article-title":"PA-824 exhibits time-dependent activity in a murine model of tuberculosis","volume":"55","author":"Ahmad","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib90","first-page":"69","article-title":"Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis","volume":"12","author":"Hu","year":"2008","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib91","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1128\/AAC.00074-08","article-title":"Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis","volume":"52","author":"Nuermberger","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib92","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1128\/AAC.00686-08","article-title":"Enhanced bactericidal activity of rifampin and\/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis","volume":"52","author":"Tasneen","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib93","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1128\/AAC.01389-08","article-title":"Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation","volume":"53","author":"Sung","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib94","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/AAC.01471-09","article-title":"Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs","volume":"54","author":"Garcia-Contreras","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib95","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1128\/AAC.00106-09","article-title":"Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib96","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1128\/AAC.00112-09","article-title":"Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib97","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1128\/AAC.01354-09","article-title":"Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients","volume":"54","author":"Diacon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib98","unstructured":"PA-824 clinicaltrials.gov (NCT ID: NCT01215851 and NCT00944021)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib99","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1021\/jm060957y","article-title":"Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles","volume":"49","author":"Sasaki","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib100","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in\u00a0vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib101","doi-asserted-by":"crossref","first-page":"949","DOI":"10.5588\/ijtld.10.0616","article-title":"Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients","volume":"15","author":"Diacon","year":"2011","journal-title":"Int. J. Tubercul. Lung Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib102","unstructured":"OPC-67683 clinicaltrials.gov (NCT ID: NCT01131351 and NCT00685360)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib103","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dki319","article-title":"Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines","volume":"56","author":"Protopopova","year":"2005","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib104","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1021\/cc020071p","article-title":"Combinatorial lead optimization of [1,2]-Diamines based on ethambutol as potential antituberculosis preclinical candidates","volume":"5","author":"Lee","year":"2003","journal-title":"J.\u00a0Comb. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib105","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ejmech.2010.01.046","article-title":"Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates","volume":"45","author":"Onajole","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib106","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1124\/jpet.105.087817","article-title":"Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N\u2032-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv","volume":"315","author":"Jia","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejmech.2012.02.033_bib107","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jac\/dkl227","article-title":"Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in\u00a0vitro","volume":"58","author":"Chen","year":"2006","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib108","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/AAC.01601-09","article-title":"In\u00a0vitro interactions between new antitubercular drug candidates SQ109 and TMC207","volume":"54","author":"Reddy","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib109","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1128\/AAC.01326-06","article-title":"Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs","volume":"51","author":"Nikonenko","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.bjp.0705984","article-title":"Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug","volume":"144","author":"Jia","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib111","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.bjp.0706650","article-title":"Interspecies pharmacokinetics and in\u00a0vitro metabolism of SQ109","volume":"147","author":"Jia","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib112","unstructured":"Sequella press release."},{"key":"10.1016\/j.ejmech.2012.02.033_bib113","unstructured":"SQ109 clinicaltrials.gov (NCT ID: NCT01218217)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib114","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/jm9509556","article-title":"Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections","volume":"39","author":"Brickner","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib115","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/anie.200200528","article-title":"Oxazolidinone structure\u2013activity relationships leading to linezolid","volume":"42","author":"Barbachyn","year":"2003","journal-title":"Ang. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2012.02.033_bib116","unstructured":"B. Pearlman, A. W. Perrault, R. M. Barbachyn, R. P. Manninen, R. D. Toops, S. D. Houser, J. T. Fleck, Process to prepare oxazolidinones, WO\/1997\/037980 (1997)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib117","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1359-6446(05)03626-3","article-title":"New drug candidates and therapeutic targets for tuberculosis therapy","volume":"11","author":"Zhang","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2012.02.033_bib118","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1128\/AAC.01297-10","article-title":"Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480","volume":"55","author":"Alffenaar","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib119","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1128\/AAC.47.1.416-417.2003","article-title":"In\u00a0vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs","volume":"47","author":"Alcala","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib120","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0924-8579(02)00239-X","article-title":"In\u00a0vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis","volume":"20","author":"Rodr\u00edguez","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2012.02.033_bib121","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","article-title":"Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib122","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","article-title":"Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis","volume":"178","author":"Dietze","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib123","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jac\/dki148","article-title":"Linezolid for the treatment of multidrug-resistant tuberculosis","volume":"56","author":"Fortun","year":"2005","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib124","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/dkl298","article-title":"Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis","volume":"58","author":"Park","year":"2006","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/648675","article-title":"Linezolid in the treatment of multidrug-resistant tuberculosis","volume":"50","author":"Schecter","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib126","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1021\/jm950956y","article-title":"Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity","volume":"39","author":"Barbachyn","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib127","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/AAC.01182-08","article-title":"Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model","volume":"53","author":"Williams","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib128","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1164\/rccm.200904-0611OC","article-title":"Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis","volume":"180","author":"Williams","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib129","unstructured":"PNU-100480 clinicaltrials.gov (NCT ID: NCT00871949 and NCT00990990)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib130","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/655471","article-title":"Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers","volume":"202","author":"Wallis","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2012.02.033_bib131","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1128\/AAC.01179-10","article-title":"Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis","volume":"55","author":"Wallis","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib132","unstructured":"PNU-100480 clinicaltrials.gov (NCT ID: NCT01225640)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib133","unstructured":"AZD5847 clinicaltrials.gov (NCT ID: NCT01037725 and NCT01116258)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib134","unstructured":"V. Balasubramanian, S. Butler, AZD5847, WGND Annual Meeting, Lille, France (2011)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib135","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/jac\/dkn136","article-title":"Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in\u00a0vitro emergence of quinolone-resistant Streptococcus pneumoniae","volume":"62","author":"Okumura","year":"2008","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib136","series-title":"Dc-159a, A Novel Quinolone, Showed High Inhibitory Activity Against Altered Topoisomerases of Streptococcus Pneumonia and Mycobacterium Tuberculosis","author":"Onodera","year":"2007"},{"key":"10.1016\/j.ejmech.2012.02.033_bib137","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1128\/AAC.00417-10","article-title":"Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone","volume":"55","author":"Sekiguchi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib138","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1128\/AAC.01545-09","article-title":"In\u00a0vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium Species","volume":"54","author":"Disratthakit","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib139","unstructured":"N. Doi, A. Disratthakit, S. Ogiso, U. S., Y. Kurosaka, In\u00a0vivo efficacy of DC-159a, a new generation of respiratory quinolone, against experimental murine tuberculosis due to multi-drug-resistant Mycobacterium tuberculosis, Abstr. 46th Intersci. Conf. AntimIcrob. Agents Chemother, American Society for Microbiology, San Francisco., abstra. F1\u20130492 (2006)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib140","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1128\/AAC.01514-10","article-title":"Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis","volume":"55","author":"Ahmad","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib141","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bmcl.2009.10.135","article-title":"Discovery of dipiperidines as new antitubercular agents","volume":"20","author":"Bogatcheva","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2012.02.033_bib142","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1016\/j.bmcl.2011.07.015","article-title":"Identification of SQ609 as a lead compound from a library of dipiperidines","volume":"21","author":"Bogatcheva","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2012.02.033_bib143","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.1171583","article-title":"Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis","volume":"324","author":"Makarov","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2012.02.033_bib144","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1080\/00397919908085943","article-title":"An efficient synthesis of formylmethyl piperidine-1-carbodithioate diethyl acetal and analogs","volume":"29","author":"Ge","year":"1999","journal-title":"Synth. Commun."},{"key":"10.1016\/j.ejmech.2012.02.033_bib145","unstructured":"V. Makarov, U. M\u00f6llmann, S.T. Cole, New benzothiazinone derivatives and their use as antibacterial agents, WO2007134625 (2007)."},{"key":"10.1016\/j.ejmech.2012.02.033_bib146","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1128\/AAC.01676-09","article-title":"Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones","volume":"54","author":"Pasca","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2012.02.033_bib147","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1365-2958.2010.07277.x","article-title":"Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance","volume":"77","author":"Manina","year":"2010","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib148","doi-asserted-by":"crossref","first-page":"e1000645","DOI":"10.1371\/journal.ppat.1000645","article-title":"High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors","volume":"5","author":"Christophe","year":"2009","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejmech.2012.02.033_bib149","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cbpa.2011.05.023","article-title":"High-content screening in infectious diseases","volume":"15","author":"Brodin","year":"2011","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib150","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2958.2003.03809.x","article-title":"EthR, a repressor of the TetR\/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator","volume":"51","author":"Engohang-Ndong","year":"2004","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2012.02.033_bib151","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nm.1950","article-title":"Synthetic EthR inhibitors boost antituberculous activity of ethionamide","volume":"15","author":"Willand","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2012.02.033_bib152","doi-asserted-by":"crossref","first-page":"9994","DOI":"10.1073\/pnas.0800663105","article-title":"A\u00a0synthetic mammalian gene circuit reveals antituberculosis compounds","volume":"105","author":"Weber","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ejmech.2012.02.033_bib153","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.4155\/bio.11.88","article-title":"MALDI imaging techniques dedicated to drug-distribution studies","volume":"3","author":"Bonnel","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ejmech.2012.02.033_bib154","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1021\/jm200076a","article-title":"Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors","volume":"54","author":"Flipo","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2012.02.033_bib155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1021\/jm200825u","article-title":"Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors","volume":"55","author":"Flipo","year":"2012","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523412001249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523412001249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:36:28Z","timestamp":1640910988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523412001249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":155,"alternative-id":["S0223523412001249"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2012.02.033","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}